Skip to Content
Merck

Key Documents

View All Documentation

Skip To

S-021

Sertraline hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice

About This Item

Empirical Formula (Hill Notation):
C17H18Cl3N
CAS Number:
79559-97-0
Molecular Weight:
342.69
UNSPSC Code:
41116107
NACRES:
NA.24
EC Number:
200-659-6
MDL number:
MFCD00895772
Pricing and availability is not currently available.
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

Cl.CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c3ccccc13

InChI

1S/C17H17Cl2N.ClH/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11;/h2-6,8,10,12,17,20H,7,9H2,1H3;1H/t12-,17-;/m0./s1

InChI key

BLFQGGGGFNSJKA-XHXSRVRCSA-N

Gene Information

human ... SLC6A4(6532)

General description

Sertraline, marketed as the brand drug Zoloft®, is an SSRI antidepressant used in the treatment of major depression as well as obsessive-compulsive, panic, and social anxiety disorders. This Certified Snap-N-Spike® Solution is applicable for use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology, and forensic analysis.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zoloft is a registered trademark of Pfizer, Inc.

Disclaimer

Supply conditions do not apply to the regions and states of Brazil: North, Northeast, Mato Grosso do Sul, Mato Grosso, and Rio Grande do Sul.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
Y0000828BP883PHR2535
Sertraline hydrochloride solution 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Supelco

S-021

Sertraline hydrochloride solution

Sertraline hydrochloride European Pharmacopoeia (EP) Reference Standard

Y0000828

Sertraline hydrochloride

Sertraline hydrochloride British Pharmacopoeia (BP) Reference Standard

BP883

Sertraline hydrochloride

Sertraline hydrochloride Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR2535

Sertraline hydrochloride

application(s)

clinical testing

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

application(s)

pharmaceutical small molecule

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

technique(s)

-

technique(s)

-

technique(s)

-

form

liquid

form

-

form

solid

form

powder

format

single component solution

format

neat

format

neat

format

-

Quality Level

300

Quality Level

-

Quality Level

-

Quality Level

300

grade

certified reference material

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

certified reference material, pharmaceutical secondary standard

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Aquatic Chronic 1 - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk

WGK 3

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Alastair J Flint et al.
BMC psychiatry, 13, 38-38 (2013-01-29)
Psychotic depression (PD) is a severe disabling disorder with considerable morbidity and mortality. Electroconvulsive therapy and pharmacotherapy are each efficacious in the treatment of PD. Expert guidelines recommend the combination of antidepressant and antipsychotic medications in the acute pharmacologic treatment
Latif Moradveisi et al.
The British journal of psychiatry : the journal of mental science, 202(3), 204-211 (2013-02-09)
Behavioural activation might be a viable alternative to antidepressant medication for major depressive disorder. To compare the effectiveness of behavioural activation and treatment as usual (TAU, antidepressant medication) for major depressive disorder in routine clinical practice in Iran. Patients with
Andre R Brunoni et al.
JAMA psychiatry, 70(4), 383-391 (2013-02-08)
Transcranial direct current stimulation (tDCS) trials for major depressive disorder (MDD) have shown positive but mixed results. To assess the combined safety and efficacy of tDCS vs a common pharmacological treatment (sertraline hydrochloride, 50 mg/d). Double-blind, controlled trial. Participants were
View All Related Papers

Global Trade Item Number

SKUGTIN
S-021-1ML04061836829339

Questions

Reviews

No rating value

Active Filters